DaVita and Medtronic form joint venture to create independent kidney-care device company

DAVITA INC.

Equal equity stakes; Medtronic contributes Renal Care Solutions; DaVita pays $75M cash and $25M other assets.
Each contributes $200M cash to launch NewCo; up to $300M milestone payments possible through 2028.
Expected close in 2023, subject to HSR and other regulatory approvals.
DaVita expects quarterly charges ~$20M after close, decreasing to zero in 2-3 years as NewCo reaches breakeven.
Independent management and six-person board with two directors from each parent plus two independents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.